Etanercept and urticaria in patients with juvenile idiopathic arthritis

Clin Exp Rheumatol. 2000 Jul-Aug;18(4):533-4.

Abstract

Etanercept, a tumor necrosis factor receptor p75 Fc fusion protein (TNFR:Fc; Enbrel), has preliminarily been shown to be effective in the management of methotrexate-resistant polyarticular juvenile idiopathic arthritis (JIA). Reported side-effects have been minor, for example injection site reactions and upper respiratory tract infections, not necessitating discontinuation of the medication (1, 2). We report on 2 patients who developed an urticaria-like rash with prurigo appearing bilaterally on the extensor surfaces of the elbows subsequent to etanercept injections.

Publication types

  • Case Reports

MeSH terms

  • Antirheumatic Agents / adverse effects*
  • Arthritis, Juvenile / drug therapy*
  • Child, Preschool
  • Elbow
  • Etanercept
  • Female
  • Humans
  • Immunoglobulin G / adverse effects*
  • Receptors, Tumor Necrosis Factor
  • Urticaria / chemically induced*

Substances

  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Etanercept